Clinical Trials Browser

Interventional × TIC10 compound × Plasma cell × Clear all

NCT02863991 2024-07-03

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

17 enrolled 10 charts

Multiple Myeloma

NCT02609230 2021-06-04

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Phase 1 Completed

Multiple Myeloma